These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33604689)

  • 1. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.
    Frood R; Burton C; Tsoumpas C; Frangi AF; Gleeson F; Patel C; Scarsbrook A
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3198-3220. PubMed ID: 33604689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prognostic Value of
    Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
    Xie M; Wu K; Liu Y; Jiang Q; Xie Y
    Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
    Guo B; Tan X; Ke Q; Cen H
    PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
    Zhang YY; Song L; Zhao MX; Hu K
    Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Overall Survival and Progression-Free Survival by the
    Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
    Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the prognostic values of
    Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
    Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma.
    Baratto L; Wu F; Minamimoto R; Hatami N; Liang T; Sabile J; Advani RH; Mittra E
    Nucl Med Commun; 2021 Jul; 42(7):792-799. PubMed ID: 33741852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic value of the metabolic volumetric parameters calculated with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Rodríguez Carrillo JL; Dotor de Lama A; Navarro Matilla MB; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):215-222. PubMed ID: 35469793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.
    Mikhaeel NG; Smith D; Dunn JT; Phillips M; Møller H; Fields PA; Wrench D; Barrington SF
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1209-19. PubMed ID: 26902371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
    Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
    Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
    Ceriani L; Milan L; Cascione L; Gritti G; Dalmasso F; Esposito F; Pirosa MC; Schär S; Bruno A; Dirnhofer S; Giovanella L; Hayoz S; Mamot C; Rambaldi A; Chauvie S; Zucca E
    Hematol Oncol; 2022 Feb; 40(1):11-21. PubMed ID: 34714558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of body composition and metabolic parameters extracted from baseline
    Chen Y; Chen Z; Tan X; Zhang Q; Zhou Y; Yuan H; Jiang L
    Ann Hematol; 2023 Oct; 102(10):2779-2789. PubMed ID: 37530853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.